Stereotactic ablative radiotherapy ( SABR ) for inoperable stage I NSCLC has shown promising results , but two independent , randomised , phase @ trials of SABR in patients with operable stage I NSCLC ( STARS and ROSEL ) closed early due to slow accrual .